BD Interventional segment generated worldwide revenues of $1.26 billion, down 2.2% from the year-ago quarter on a reported basis and 1.1% both at CER and on an organic basis.

BD is considering a share swap deal with smaller diagnostics firms, such as Waters Corporation, Qiagen and Revvity. Under this structure, BD would merge the Life Sciences unit with a listed entity ...

Waters Corporation (NYSE: WAT) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, ...